Abstract 280P
Background
Abiraterone (ABI) and enzalutamide (ENZ) are preferred as 1st-line therapy for mCRPC. Ra-223 has survival impacts for mCRPC with symptomatic bone mets but no benefit in combination with ABI/ENZ. Very few pts wanted to receive chemotherapy due to old age and could not afford NGS or PSMA scan. 40% pts received Ra-223 as 2nd-line therapy after ABI/ENZ and lymph nodes (LNs) < 3 cm in short-axis were enrolled in the ALSYMPCA trial. We reported the outcome of mCRPC pts with bone mets receiving Ra-223 as 2nd-line therapy after ABI/ENZ.
Methods
We collected data that pts using ABI/ENZ as 1st-line therapy for mCRPC and symptomatic bone mets followed by Ra-223. Pts received docetaxel in mCSPC were excluded. We evaluated the clinical outcomes of this population.
Results
From Jan 2020 to Jun 2023, 13 pts received Ra-223 as 2nd-line. Median follow-up was 15.7 mos (1.7-27.3). Median radiographic PFS was 6.5 mos and median OS was 10.2 mos. 7 pts had mediastinal or paraaortic lymph nodes (LNs) in CT scan before Ra-223. 10 pts had PSA progression during Ra-223 (6 of them had prominent LN and 4 could not complete 6 cycles due to lung and liver mets). 3 pts without LNs had stable PSA including 1 pt had PSA >30% reduction. The median calculated PSA doubling time (PSADT) was 5.6 mos (0.9-16) and PSADT < 3 mos passed away rapidly. For pts progression after Ra-223, they kept on ADT but no PSA response was found. 4 pts received docetaxel, enzalutamide or local RT as salvage therapies. One received oral cyclophosphamide as 4th-line after 3rd-line docetaxel and had a PSA reduction >50% and was still alive >12 mos without progression. The major adverse effect of Ra-223 was Gr. 3 anemia. 4 pts decreased opioid use after Ra-223. Table: 280P
Patients' characteristics | N = 13 |
Mean age (years) | 79 [62 - 93] |
ECOG PS 0-1 | 7 |
ECOG PS >=2 | 6 |
Gleason score | |
3+4 | 4 |
4+5 | 8 |
5+5 | 1 |
Initial T stage | |
T2 | 1 |
T3 | 9 |
T4 | 3 |
Initial N stage | |
N0 | 4 |
N1 | 9 |
Local RT to prostate or prostatectomy | 8 |
Bone metastases at diagnosis | 12 |
First-line treatment for mCRPC | Abiraterone (ABI): 10 |
Enzalutamide (ENZ): 3 | |
Median treatment duration of ABI/ENZ (mos) | 16.7 [9.8 - 36.3] |
Median Serum PSA before Ra-223 (ng/dL) | 55.7 [4.8 - 488.7] |
Pts with lymph nodes in CT prior to Ra-223 | 7 |
Median radiographic PFS of Ra-223 (mos) | 6.5 [1.8 - 14.1] |
Sequential systemic therapies | Docetaxel: 4 (3rd-line) |
Enzalutamide: 1 (4rd-line) | |
Oral cyclophosphamide: 1 (4th-line) | |
Median OS of Ra-223 (mos) | 10.2 [2.0 - 25.6] |
Conclusions
Ra-223 use after first-line ABI/ENZ for mCRPC with bone mets should be cautious if pts had prominent LNs. PSA progression during or after Ra-223 leads to poor outcome and salvage therapy should be given earlier.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract